With sepsis, every hour counts
Target therapy sooner, with species identification before the second dose of empiric therapy

T2Bacteria and T2Candida are the first and only FDA-cleared diagnostic tests to provide species identification of sepsis-causing bacterial and fungal pathogens, directly from a whole blood sample, independent of a positive blood culture.

T2Biothreat Panel: Now FDA-cleared
T2Biothreat has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)

The T2Biothreat Panel is a direct-from-blood molecular diagnostic test that runs on the FDA-cleared T2Dx® Instrument and simultaneously detects six biothreat pathogens.

Enhancing the standard of care.

With T2 Biosystems, hospitals can identify sepsis-causing pathogens faster and more accurately than the standard of blood culture alone

Hospitals trust in T2MR Technology

Demonstrated 47% reduction in antifungal therapy.
Henry Ford Health System
Realized 7 days reduction in median length of stay in the ICU.
Lee Health
T2Bacteria positive results 20 hours sooner than blood culture.
Huntsville Hospital
Saved ~$280 pharmacy costs per patient.
Robert Wood Johnson Medical School
Identified escalation and de-escalation opportunities in patients tested with T2Candida.
Riverside Community Hospital
100% of patients who tested positive received appropriate therapy in <9 hours

Patient Case Studies

Real stories about the positive impact of T2 Biosystems on clinical decisions and outcomes

Numbers don't lie.

Sepsis is a burden on healthcare and patients, contributing to:

1 in 2-3
US hospital deaths.
11 million
deaths annually, worldwide.
$62 billion
in US healthcare costs.
Integrate T2 Biosystems panels into your hospital today!